Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
ArcDia will provide Xinhua its biochemical assay components and R&D services in order to localize the Finnish firm's MariPOC testing platform in China.
The biomarkers — ubiquitin carboxyl terminal hydrolase-L1 and glial fibrillary acidic protein — can be detected in blood soon after a brain injury.
The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.
The firm said that expression levels of GDF15 can be used to determine the severity of glaucoma, one of the leading causes of blindness.
Epigenomics terminated its collaboration with China's BioChain for the licensing of the septin9 marker and exclusive Chinese distribution rights for Epi proColon.
The test uses qPCR to measure the methylation level of three bladder cancer-specific biomarkers in patient urine samples.
Galaxy has licensed IP from Proteome Sciences for the development of a test for the diagnosis and timing of stroke onset to help inform treatment decisions.
Genfit's assay will be deployed through Covance's central laboratories to validate its use to better identify and characterize patients with the liver disease.
The New York Department of Health-certified tests are based on proprietary algorithms licensed from Columbia University, which offers them in the US.